Physician profile
Antoine E Chahine
NPI 1205879491
$21,795.72
in general payments reported to CMS, 2019-2025
89 companies · $3,841 in 2025
The $3,841 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,507 · 2020: $1,638 · 2021: $2,490 · 2022: $3,111 · 2023: $4,023 · 2024: $3,185 · 2025: $3,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,726.21 |
| Education | $322.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,973.95 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $1,323.90 | 2019-2025 | |
| Asd Specialty Healthcare, LLC | $1,143.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,003.89 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $923.84 | 2019-2023 | Lumakras, Xgeva, Nplate |
| Astrazeneca Pharmaceuticals LP | $896.45 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Genzyme Corporation | $749.04 | 2019-2025 | |
| Daiichi Sankyo INC. | $676.12 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Incyte Corporation | $671.11 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Pfizer INC. | $666.32 | 2019-2025 | |
| Celgene Corporation | $662.12 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Janssen Biotech, INC. | $643.13 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Eisai INC. | $615.93 | 2019-2025 | |
| Lilly USA, LLC | $538.72 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $512.17 | 2019-2023 | Adcetris, Tukysa, Padcev |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $502.58 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Exelixis INC. | $491.39 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $451.67 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Glaxosmithkline, LLC. | $404.43 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $397.53 | 2019-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $390.23 | 2019-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $328.54 | 2023-2025 | Yonsa, Odomzo |
| Emd Serono, INC. | $318.12 | 2020-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $304.20 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.69 | 2019-2025 | Fruzaqla, Alunbrig, Gammagard |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.57 | 2019-2025 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $255.70 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $232.28 | 2019-2023 | Imbruvica |
| Genmab U.S., INC. | $224.68 | 2021-2025 | Epkinly, Tivdak |
| Deciphera Pharmaceuticals INC. | $196.31 | 2021-2025 | Qinlock, Tgct |
| Aveo Pharmaceuticals, INC. | $195.94 | 2022-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $184.98 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $161.90 | 2019-2025 | Provenge |
| Blueprint Medicines Corporation | $161.23 | 2020-2025 | Ayvakit |
| Gilead Sciences, INC. | $133.43 | 2021-2025 | Trodelvy |
| Immunogen, INC. | $130.11 | 2023 | Elahere |
| Pharmacosmos Therapeutics INC. | $129.57 | 2023-2025 | Monoferric, Cosela |
| Teva Pharmaceuticals USA, INC. | $128.85 | 2019-2021 | |
| Puma Biotechnology, INC. | $121.26 | 2019-2025 | |
| Epizyme, INC. | $118.89 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $118.35 | 2024-2025 | Orgovyx |
| Beone Medicines USA, INC. | $115.49 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $114.93 | 2020-2024 | Brukinsa |
| Tersera Therapeutics LLC | $113.77 | 2023-2025 | Zoladex, Xermelo |
| Lexicon Pharmaceuticals, INC. | $106.81 | 2019-2020 | |
| Taiho Oncology, INC. | $106.60 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $98.90 | 2019-2025 | Ultomiris |
| Acrotech Biopharma INC. | $97.93 | 2021-2025 | Beleodaq |
| Array Biopharma INC | $97.11 | 2022-2024 | Lorbrena, Mektovi, Braftovi |
| Tesaro, INC. | $92.89 | 2019 | |
| Stemline Therapeutics INC. | $74.26 | 2023-2025 | Orserdu |
| Emmaus Medical, INC. | $74.09 | 2020-2024 | Endari |
| Tempus Ai, INC | $67.67 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $56.58 | 2021-2025 | Xpovio |
| Adc Therapeutics America, INC. | $52.35 | 2022-2023 | |
| Spectrum Pharmaceuticals INC. | $48.51 | 2023-2025 | Rolvedon |
| Agios Pharmaceuticals, INC. | $47.14 | 2024-2025 | Pyrukynd |
| Kite Pharma, INC. | $44.54 | 2022-2025 | Yescarta |
| Mirati Therapeutics, INC. | $44.02 | 2023 | Krazati |
| Clovis Oncology, INC. | $43.39 | 2019-2022 | |
| G1 Therapeutics, INC. | $41.09 | 2022-2023 | Cosela |
| Servier Pharmaceuticals LLC | $40.85 | 2024-2025 | |
| Caris Mpi, INC. | $39.65 | 2025 | Mi Cancer Seek |
| Eusa Pharma (US) LLC | $36.86 | 2020-2022 | |
| Springworks Therapeutics, INC. | $34.66 | 2025 | Ogsiveo |
| Mylan Institutional INC. | $32.06 | 2019-2023 | Fulphila |
| Kyowa Kirin, INC. | $31.64 | 2024-2025 | Poteligeo |
| Azurity Pharmaceuticals, INC. | $29.42 | 2024-2025 | Vivimusta, Danziten |
| Cti Biopharma Corp. | $29.41 | 2022 | |
| Acceleron Pharma, INC. | $26.91 | 2021 | |
| Myriad Genetic Laboratories, INC. | $26.22 | 2024 | Mychoice Cdx |
| Invivyd INC | $25.09 | 2025 | Pemgarda |
| Accord Healthcare, INC. | $24.60 | 2023 | |
| Pharmaessentia USA Corporation | $23.84 | 2023 | Besremi |
| Tolmar, INC. | $22.51 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $22.51 | 2025 | Rubraca |
| Aurobindo Pharma USA, INC. | $20.30 | 2020 | |
| Apellis Pharmaceuticals, INC. | $19.91 | 2023 | Empaveli |
| Adaptive Biotechnologies Corporation | $18.47 | 2022 | |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Morphosys, US INC. | $17.81 | 2023 | Monjuvi |
| Helsinn Therapeutics (U.S.), INC. | $17.30 | 2019 | |
| Verity Pharmaceuticals INC. | $15.79 | 2024 | Trelstar |
| Secura Bio, INC. | $15.33 | 2020 | |
| Heron Therapeutics, INC. | $14.50 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.77 | 2020 | |
| Myovant Sciences INC. | $12.95 | 2022 | |
| Sobi, INC | $12.50 | 2022 | |
| Rigel Pharmaceuticals, INC. | $11.20 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
Opdivo $812Keytruda $510Sarclisa $355Epkinly $338Imbruvica $295Cabometyx $270Lynparza $266Lenvima $248Libtayo $237Enhertu $227Xtandi $224Orgovyx $195Jaypirca $189Reblozyl $179Pluvicto $173Verzenio $172Venclexta $171Welireg $169Odomzo $164Yonsa $164Kisqali $161Ojjaara $160Opdualag $152Elahere $149Fotivda $141Injectafer $137Brukinsa $131Provenge $130Monjuvi $125Padcev $123Ayvakit $123Tukysa $120Scemblix $120Darzalex $117Zepzelca $117Cablivi $115Talvey $114Monoferric $106Retevmo $104Qinlock $101Enjaymo $93.11Bavencio $91.77Onivyde $87.60Ibrance $87.27Tivdak $87.15Jakafi $83.49Calquence $82.97Trodelvy $82.71Nubeqa $78.47Orserdu $74.26Rybrevant $73.75Pemazyre $70.13Zoladex $69.58Adcetris $69.27Tazverik $68.05Inqovi $62.17Lonsurf $62.17Ultomiris $61.89Datroway $61.44Lorbrena $61.20Xalkori $61.20Keytruda Qlex $60.55Fruzaqla $58.24Jemperli $57.38Zejula $57.38Stivarga $56.78Beleodaq $56.71Polivy $55.71Talzenna $55.31Piqray $54.96Elitek $54.26Inlyta $53.90Rolvedon $48.51Elrexfio $48.04Shingrix $47.31Pyrukynd $47.14Lumakras $46.34Braftovi $46.00Mektovi $46.00Imfinzi $45.46Rubraca $45.02Cosela $44.48Xermelo $44.19Krazati $44.02Xofigo $43.16Lunsumio $40.47Mi Cancer Seek $39.65Xpovio $38.37Tecentriq $37.89Gilotrif $37.19Nerlynx $36.97Tecvayli $35.32Vitrakvi $35.31Ogsiveo $34.66Lutathera $34.13Itovebi $33.95Perjeta $33.50Alunbrig $33.35Yescarta $32.24Poteligeo $31.64
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Chahine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.